Patents by Inventor Leyi Gong
Leyi Gong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10472391Abstract: Certain embodiments are directed to compositions and methods of inhibiting a pathogenic bacterial infection involving ADAM10, specifically a method for treating pore-forming toxin-inducted pathology caused by exposure to staphylococcus in a subject, comprising administering an effective amount of a ADAM10 inhibitor to a patient. The methods include treating pneumonia or inhibiting disruption to epithelial barrier in a subject, having or at risk of developing staphylococcal infection.Type: GrantFiled: April 4, 2014Date of Patent: November 12, 2019Assignees: THE UNIVERSITY OF CHICAGO, SRI INTERNATIONALInventors: Juliane Bubeck Wardenburg, Katherine Weh, Leyi Gong
-
Patent number: 8642601Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.Type: GrantFiled: June 2, 2011Date of Patent: February 4, 2014Assignee: Roche Palo Alto LLCInventors: Humberto Bartolome Arzeno, Lubov K. Filonova, David Michael Goldstein, Leyi Gong, Bradley E. Loe, Erin M. O'Brien, Wylie Solang Palmer, David Mark Rotstein, Tania M. Silva, Yun-Chou Tan
-
Patent number: 8536172Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein p, q, Y?, r, R1, R2, X, X1, X2, X3, and X4 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: GrantFiled: August 9, 2010Date of Patent: September 17, 2013Assignee: Roche Palo Alto LLCInventors: Leyi Gong, Xiaochun Han, Ferenc Makra, Wylie Solang Palmer, Lubica Raptova
-
Patent number: 8404695Abstract: This application discloses novel pyrimidinyl pyridone derivatives according to Formula I, wherein R1, R2, and R3 are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of Formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of Formula I to a subject in need thereof.Type: GrantFiled: October 22, 2009Date of Patent: March 26, 2013Assignee: Roche Palo Alto LLCInventors: Genevieve N. Boice, Leyi Gong, Kristen Lynn McCaleb, Wylie Solang Palmer
-
Patent number: 8399462Abstract: Compounds of formula I modulate JNK: wherein the variables are as defined herein.Type: GrantFiled: December 7, 2007Date of Patent: March 19, 2013Assignee: Roche Palo Alto LLCInventors: James Patrick Dunn, Leyi Gong, David Michael Goldstein, Xiaochun Han, Joan Heather Hogg, Wylie Solang Palmer, Lubica Raptova, Tania Silva, Parcharee Tivitmahaisoon, Teresa Alejandra Trejo-Martin, Christophe Michoud, Achyutharao Sidduri
-
Patent number: 8268840Abstract: This application discloses novel pyrimidinyl pyridone derivatives according to formula I, wherein A, R1, R2, R3, and m are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of formula I to a subject in need thereof.Type: GrantFiled: April 29, 2009Date of Patent: September 18, 2012Assignee: Roche Palo Alto LLCInventors: Frederick Brookfield, Florence Eustache, Michael Patrick Dillon, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Jaehyeon Park, Deborah Carol Reuter, Eric Brian Sjogren
-
Patent number: 8227478Abstract: Compounds of formula I modulate JNK: wherein X1 and X2 are each simultaneously N or CH; X3 is CH—R2 or N—SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 10, 2009Date of Patent: July 24, 2012Assignee: Roche Palo Alto LLCInventors: Leyi Gong, Alam Jahangir, Deborah Carol Reuter
-
Patent number: 8183254Abstract: The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R1, R2, R3, X, X1, X2, X3, X4, X5, Y1, Y2, Z1 and Z2 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: GrantFiled: May 14, 2009Date of Patent: May 22, 2012Assignee: Roche Palo Alto LLCInventors: Humberto Bartolome Arzeno, James Patrick Dunn, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Alam Jahangir, Wylie Solang Palmer, Deborah Carol Reuter, Tania Silva, Parcharee Tivitmahaisoon, Teresa Alejandra Trejo-Martin, Shao-Yong Wu
-
Patent number: 8163906Abstract: Compounds of formula I are effective modulators of JNK: wherein X is CR11 or N; Y is —C(O)R3, 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R1 and R2; R1 and R2 are each independently H, halo, CN, lower alkyl, or —Y1—Y2—Y3—R8, or R1 and R2 together form —O(CH2)nO—, where n is 1 or 2; Y1 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —S—, —SO2—, or a bond; Y2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y3 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —SO2—, or a bond; R8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR9R10, wherein R8 other than H is optionally substituted with lower alkyl, halo, —CF3, or —OH; R9 and R10 are each independently H or lower alkyl; R3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR9R10; R4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroType: GrantFiled: May 14, 2008Date of Patent: April 24, 2012Assignee: Roche Palo Alto, LLCInventors: Sarah C. Abbot, Geneviève N. Boice, Bernd Buettelmann, David Michael Goldstein, Leyi Gong, Joan Heather Hogg, Pravin Iyer, Kristen Lynn McCaleb, Yun-chou Tan
-
Publication number: 20110301171Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof, wherein R5 is a group of formula (a) or (b): and wherein m, n, p, q, X, Y, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.Type: ApplicationFiled: June 2, 2011Publication date: December 8, 2011Inventors: Humberto Bartolome Arzeno, Lubov K. Filonova, David Michael Goldstein, Leyi Gong, Bradley E. Loe, Erin M. O'Brien, Wylie Solang Palmer, David Mark Rotstein, Tania M. Silva, Yun-Chou Tan
-
Publication number: 20110301170Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof, wherein: wherein m, n, p, q, X Y, Z, A, R1, R2, R3, R4, R5 and Y6 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity.Type: ApplicationFiled: June 2, 2011Publication date: December 8, 2011Inventors: Leyi Gong, Yun-Chou Tan
-
Publication number: 20110034470Abstract: The invention relates to JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses JNK inhibitors, as described below in Formula I: wherein p, q, Y?, r, R1, R2, X, X1, X2, X3, and X4 are as defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: ApplicationFiled: August 9, 2010Publication date: February 10, 2011Inventors: Leyi Gong, Xiaochun Han, Ferenc Makra, Wylie Solang Palmer, Lubica Raptova
-
Patent number: 7868031Abstract: The present invention relates to propionamide compounds of formula I for use as antiinflammatory agents: wherein R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and pharmaceutical compositions comprising the compounds of formula I.Type: GrantFiled: December 8, 2006Date of Patent: January 11, 2011Assignee: Roche Palo Alto LLCInventors: Leyi Gong, Counde O'Yang, Yun-chou Tan
-
Publication number: 20100160360Abstract: Compounds of formula I modulate JNK: wherein X1 and X2 are each simultaneously N or CH; X3 is CH—R2 or N—SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is where R3 is H, lower acyl, or an amino acid, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 10, 2009Publication date: June 24, 2010Inventors: Leyi Gong, Alam Jahangir, Deborah Carol Reuter
-
Publication number: 20100099691Abstract: This application discloses novel pyrimidinyl pyridone derivatives according to Formula I, wherein R1, R2, and R3 are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of Formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of Formula I to a subject in need thereof.Type: ApplicationFiled: October 22, 2009Publication date: April 22, 2010Inventors: Genevieve N. BOICE, Leyi GONG, Kristen Lynn MCCALEB, Wylie Solang PALMER
-
Publication number: 20090318484Abstract: The invention relates to prodrugs of JNK inhibitors and corresponding methods, formulations, and compositions for inhibiting JNK and treating JNK-mediated disorders. The application discloses prodrugs of JNK inhibitors, as described below in formula I: wherein m, n, p, q, Q, r, R1, R2, R3, X, X1, X2, X3, X4, X5, Y1, Y2, Z1 and Z2 areas defined herein. The compounds and compositions disclosed herein are useful to modulate the activity of JNK and treat diseases associated with JNK activity. Disclosed are methods and formulations for inhibiting JNK and treating JNK-mediated disorders, and the like, with the compounds, and processes for making said compounds, and corresponding compositions, disclosed herein.Type: ApplicationFiled: May 14, 2009Publication date: December 24, 2009Inventors: Humberto Bartolome Arzeno, James Patrick Dunn, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Alam Jahangir, Wylie Solang Palmer, Deborah Carol Reuter, Tania Silva, Parcharee Tivitmanhaisoon, Teresa Alejandra Trejo-Martin, Shao-Yong Wu
-
Publication number: 20090270389Abstract: This application discloses novel pyrimidinyl pyridone derivatives according to formula I, wherein A, R1, R2, R3, and m are defined as described herein, which inhibit JNK. The compounds disclosed herein are useful to modulate the activity of JNK and treat diseases associated with excessive JNK activity. The compounds are useful to treat autoimmune, inflammatory, metabolic, and neurological diseases as well as cancer. Also disclosed are compositions comprising the compound of formula I and methods of treatment comprising administering a therapeutically effective amount of the compound of formula I to a subject in need thereof.Type: ApplicationFiled: April 29, 2009Publication date: October 29, 2009Inventors: Frederick Brookfield, Florence Eustache, Michael Patrick Dillon, David Michael Goldstein, Leyi Gong, Xiaochun Han, Joan Heather Hogg, Jaehyeon Park, Deborah Carol Reuter, Eric Brian Sjogren
-
Patent number: 7476676Abstract: This invention relates to the use of inhibitors of glycogen synthase kinase-3? to increase bone formation.Type: GrantFiled: January 9, 2003Date of Patent: January 13, 2009Assignee: Roche Palo Alto LLCInventors: Patricia Ann Day-Lollini, Leyi Gong
-
Publication number: 20080287458Abstract: Compounds of formula I are effective modulators of JNK: wherein X is CR11 or N; Y is —C(O)R3, 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R1 and R2; R1 and R2 are each independently H, halo, CN, lower alkyl, or —Y1—Y2—Y3—R8, or R1 and R2 together form —O(CH2)nO—, where n is 1 or 2; Y1 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —S—, —SO2—, or a bond; Y2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y3 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —SO2—, or a bond; R8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR9R10, wherein R8 other than H is optionally substituted with lower alkyl, halo, —CF3, or —OH; R9 and R10 are each independently H or lower alkyl; R3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR9R10; R4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydroxyType: ApplicationFiled: May 14, 2008Publication date: November 20, 2008Inventors: Sarah C. Abbot, Genevieve N. Boice, Bernd Buettelmann, David Michael Goldstein, Leyi Gong, Joan Heather Hogg, Pravin Iyer, Kristen Lynn McCaleb, Yun-chou Tan
-
Publication number: 20080146565Abstract: Compounds of formula I modulate JNK: wherein the variables are as defined herein.Type: ApplicationFiled: December 7, 2007Publication date: June 19, 2008Inventors: James Patrick Dunn, Leyi Gong, David Michael Goldstein, Xiaochun Han, Joan Heather Hogg, Wylie Solang Palmer, Lubica Raptova, Tania Silva, Parcharee Tivitmahaisoon, Teresa Alejandra Trejo-Martin, Christophe Michoud, Achyutharao Sidduri